Last reviewed · How we verify
IvabRadine hemisulfate Sustained-release Tablets
IvabRadine hemisulfate Sustained-release Tablets is a Small molecule drug developed by Jiangsu HengRui Medicine Co., Ltd.. It is currently in Phase 2 development.
At a glance
| Generic name | IvabRadine hemisulfate Sustained-release Tablets |
|---|---|
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Clinical Trial of Systolic Heart Failure Treatment of IvabRadine Hemisulfate Sustained-release Tablets （FIRST） (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IvabRadine hemisulfate Sustained-release Tablets CI brief — competitive landscape report
- IvabRadine hemisulfate Sustained-release Tablets updates RSS · CI watch RSS
- Jiangsu HengRui Medicine Co., Ltd. portfolio CI
Frequently asked questions about IvabRadine hemisulfate Sustained-release Tablets
What is IvabRadine hemisulfate Sustained-release Tablets?
IvabRadine hemisulfate Sustained-release Tablets is a Small molecule drug developed by Jiangsu HengRui Medicine Co., Ltd..
Who makes IvabRadine hemisulfate Sustained-release Tablets?
IvabRadine hemisulfate Sustained-release Tablets is developed by Jiangsu HengRui Medicine Co., Ltd. (see full Jiangsu HengRui Medicine Co., Ltd. pipeline at /company/jiangsu-hengrui-medicine-co-ltd).
What development phase is IvabRadine hemisulfate Sustained-release Tablets in?
IvabRadine hemisulfate Sustained-release Tablets is in Phase 2.